Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...

Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute ...

Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer ...

You can expect Guardant Health to continue garnering more success in the coming years. With the current trajectory, the flagship (Guardant360) is generating an extremely robust revenue increase.

With a stock down nearly 50% over the last 52 weeks, investors in Guardant Health (GH -2.49%) haven't had a lot to cheer about this year. The last couple of days, however, may be changing that.

Guardant Health has seen its share price soar 78% in 2019, but it's still a relatively small company with a leading position in what could become a $100 billion market. Here's why this under-the ...